Antimicrobial Peptides Demonstrate Activity against Resistant Bacterial Pathogens

Area of Science:

• Biochemistry and Molecular Biology
• Microbiology
• Pharmacology

Background:

• The escalating antimicrobial resistance (AMR) crisis poses a significant global health threat, particularly in low- and middle-income countries.
• Emerging multi- and pan-drug resistant pathogens, including WHO priority pathogens like Klebsiella and Pseudomonas, necessitate novel antibacterial strategies.
• Last-resort antibiotics are losing efficacy, increasing the urgency for alternative treatments.

Purpose of the Study:

• To review the potential of antimicrobial peptides (AMPs) as therapeutic agents against multidrug-resistant (MDR) infections.
• To discuss the mode of action, resistance development, and formulation challenges associated with AMPs.
• To highlight clinically relevant pathogens based on the WHO priority list.

Main Methods:

• Literature review focusing on antimicrobial peptides and their application in treating drug-resistant infections.
• Analysis of AMPs' mechanisms of action, resistance profiles, and pharmacokinetic/pharmacodynamic properties.
• Identification of critical pathogens from the WHO priority list relevant to AMP therapy.

Main Results:

• Antimicrobial peptides exhibit potent, rapid-acting antibacterial properties with a low propensity for resistance development.
• AMPs possess immune-stimulating activities, enhancing their therapeutic potential in vivo.
• Significant challenges remain in large-scale production, formulation, cost-effectiveness, and protease stability for clinical translation.

Conclusions:

• Antimicrobial peptides represent a promising avenue for combating MDR infections, offering a multi-hit mechanism of action.
• Addressing production, formulation, and stability issues is crucial for the successful clinical application of AMPs.
• Further research and development are needed to harness the full therapeutic potential of AMPs against WHO priority pathogens.